Drugs / PRL3-ZUMAB
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03191682 | Feb 2017 → Feb 2027 expected | cancer | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07547228 | Oct 2025 → Feb 2027 expected | wet macular degeneration | Intra-IMMUSG Pte Ltd | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07541001 | Aug 2021 → Jun 2026 overdue | cancer | Intra-IMMUSG Pte Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04452955 | Dec 2020 → Dec 2026 expected | cancer | Intra-IMMUSG Pte Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04118114 | Sep 2019 → Oct 2025 | gastric cancer, hepatocellular carcinoma | National Cancer Centre, Singapore | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07290088 | Jan 2023 → Dec 2026 expected | high grade malignant neoplasm | Intra-IMMUSG Pte Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRL3-ZUMAB | “PRL3-zumab is a first-in-class humanized antibody that specifically binds to PRL-3 oncotarget with high affinity and has been shown to reduce tumor growth and increase survival.” PMID 37060431 ↗ Apr 20237“Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors” NCT04118114 ↗ |
| Modality | Monoclonal antibody | “The pharmacokinetics of PRL3-zumab were dose proportional, consistent with an IgG type monoclonal antibody.” PMID 37060431 ↗ Apr 2023 |
| Route | Intravenous | “IV administration every 2 weeks” NCT04118114 ↗ |